Posted in | News | Nanomedicine | Nanomagnetics

MHTX’s MRX Technology Holds Promise for Early Detection of Ovarian Cancer

Senior Scientific LLC, a subsidiary of Manhattan Scientifics, Inc., is currently collaborating with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a cancer detection and measurement technology originally developed by Edward R. Flynn, PhD. John D. Hazle, PhD of the MD Anderson Cancer Center recently presented initial results from the collaboration in a poster at the World Molecular Imaging Conference in Seoul, South Korea.

The link to the results can be found here - http://www.mhtx.com/wmic/2014-poster.pdf.

The poster concluded that Senior Scientific’s MRX technology “is unparalleled in terms of sensitivity compared to imaging-based ovarian cancer detection methods, such as TVU; thus, it holds promise for detecting ovarian cancer much earlier.”

The poster describes the MRX technology as “(based on unpublished data) it is up to 200 times more sensitive than current imaging technologies.”

The poster also noted that, “Because the technology relies on (NPs) binding to specific cancer cells and is detecting molecular markers, only cancer will presumably be detected with this technology while unbound particles in the vascular space will not be detected. Another advantage of nanomagnetic relaxometry compared to some imaging-based technologies is that it does not expose patients to potentially harmful ionizing radiation and, because this technology is considered to be safe for human use, we expect that human studies could begin within the next five years. Thus, nanomagnetic relaxometry holds promise for detecting ovarian cancer much earlier, which is crucial to increasing survivorship.” The Company hopes to accelerate its FDA submissions.

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.